Endocrine Abstracts

Introduction: Hyperfiltration (HF) is an early marker of chronic renal disease (CRD), which is prevalent in 10–15% of MS patients\. Taking into account the benefit of testosterone replacement towards MS components in men with MS and hypogonadism, we can expect the same benefit on HF.

Objective: To study the role of hypogonadism correction in patients with MS and hyperfiltration.

Methods: Of 71 men aged 35–69 with MS (IDF criteria) and hypogonadism (total testosterone (TT) < 11 nmol/l) were divided into two groups. Of 35 men were treated with testosterone undecanoate (Nebido, Schering) (group 1) and 36 men were the controls (group 2). Glomerular filtration rate (GFR) was estimated at baseline and after 6 months of treatment. GFR was counted by Cockraft–Gault formula with adjustment for standard body surface area (GFRst) and compared to population normal ranges (Nijmegen Biomedical Study 2007), resulting in HF (GFRst >110 ml/min per 1.73 m²) or normal filtration (60<GFRst<110 ml/min per 1.73 m²).

Results: Both groups did not differ (P>0.1) by the main prognostic CRD factors such as age (52.5 and 52.8 years), weight (108 and 106 kg), waist circumference (116 and 113 cm), SBP (139 and 136 mmHg), triglycerides (2.3 and 2.2 mmol/l), LDL (3.8 and 3.6 mmol/l), fasting plasma glucose (6.5 and 6.3 mmol/l), GFR (101 and 103 ml/min per 1.73 m²), as well as TT level (7.9 and 9.4 nmol/l), incidence of HF (31 and 30%) and frequency of ACEI intake (46 and 31%). After 6 months of treatment incidence of HF was lowered by 23% in group 1, and increased to 40% in group 2 (P=0.046).

Conclusion: Our results show the benefit of hypogonadism correction in men with MS towards HF lowering the risk of CRD development.